As noted in my prior post in this thread, I consider EOLS’ list price for Jeuveau a gimmick to foster marketing the product as a “high-end” option. This gimmick won’t fool anybody, IMO.
On the CC, management acknowledged that the actual Jeuveau price charged to injectors will be a discount to Botox with the size of the discount depending on the injector’s volume.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.